{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T01:35:27Z","timestamp":1789263327480,"version":"build-2803163510"},"reference-count":39,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2009,8,11]],"date-time":"2009-08-11T00:00:00Z","timestamp":1249948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Psoriasis is a chronic inflammatory skin condition that affects approximately 2% of the population. Up to 50% of patients with psoriasis have concurrent nail psoriasis, with a lifetime incidence of 80% to 90%. Up to 30% of patients with skin psoriasis also have psoriatic arthritis (PsA) and of these, approximately 80% have nail disease. However, nail involvement is often overlooked by physicians, despite the significant burden it places on patients as a result of functional impairment of manual dexterity, pain and psychological stress. Affected nail plates often thicken and crumble, and because they are very visible, patients are usually concerned about the appearance of their nails, often causing them to avoid normal day\u2010to\u2010day activities (including work). In the longer\u2010term, nail involvement may be a signal of a more severe form of psoriasis or a precursor of PsA. Conventional treatment of nail psoriasis is generally considered inconvenient by patients, and it is limited by adverse effects and often a reduction in efficacy over time. There is also a lack of controlled clinical trials\u2019 data and no consistent treatment approach has been advocated. Recently, the effects of biologic agents targeted against tumour necrosis factor alpha (TNF\u03b1) on nail psoriasis have been investigated. The multicentre, double\u2010blind EXPRESS [European Infliximab for Psoriasis (Remicade) Efficacy and Safety Study] trial revealed that infliximab 5\u00a0mg\/kg at weeks 0, 2, 6, and then every 8\u00a0weeks significantly improved nail psoriasis, evaluated using the Nail Psoriasis Severity Index (NAPSI) in 378 patients with moderate to severe psoriasis. Significant improvement was reported as early as week 10, and at week 50 full nail clearance was evident in 45% of patients receiving infliximab. There is also evidence from small studies that infliximab significantly improves nail lesions and quality of life in patients with nail psoriasis. There is a need for improving the awareness of nail psoriasis and its impact on patients\u2019 quality of life. Moreover, the potential role for nail involvement as a link between psoriasis and PsA underlines its importance and the need for effective management. Infliximab has been shown to improve psoriatic nail lesions and quality of life, and it should be considered as one of the most appropriate available treatment options for the many patients with this distressing condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conflicts of interest<\/jats:title>\n                    <jats:p>None declared.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1468-3083.2009.03364.x","type":"journal-article","created":{"date-parts":[[2009,8,11]],"date-time":"2009-08-11T13:51:50Z","timestamp":1249998710000},"page":"15-21","source":"Crossref","is-referenced-by-count":98,"title":["Approach to managing patients with nail psoriasis"],"prefix":"10.1111","volume":"23","author":[{"given":"K","family":"Reich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,8,11]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"725","article-title":"Treatment of psoriasis: an algorithm\u2010based approach for primary care physicians","volume":"61","author":"Pardasani AG","year":"2000","journal-title":"Am Fam Physician"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.07.073"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"e_1_2_6_5_2","first-page":"280","article-title":"The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient\u2010membership survey","volume":"137","author":"Kreuger GG","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12954-6"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh514"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.4103\/0022-3859.30334"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000119415"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh198"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2007.00112.x"},{"key":"e_1_2_6_13_2","first-page":"1752","article-title":"Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies","volume":"26","author":"Cohen MR","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/33.9.834"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000246274"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(05)70145-5"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24172"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.07.042"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05725.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000068469"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)00910-1"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02462.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/00015550252948220"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000018281"},{"key":"e_1_2_6_26_2","first-page":"355","article-title":"Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double\u2010blind, randomized, vehicle\u2010controlled study","volume":"68","author":"Scher RK","year":"2001","journal-title":"Cutis"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1998.tb02386.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02031.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1987.tb05834.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1001\/archderm.1980.01640330061013","article-title":"Response of psoriatic nails to oral photochemotherapy","volume":"116","author":"Marx JL","year":"1980","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)90189-2"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10227-004-0114-8"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06070.x"},{"key":"e_1_2_6_34_2","unstructured":"GianettiAet\u00a0al.(Title) Abstract FC08\u20107 spring EADV 2008 (CRYSTEL)."},{"key":"e_1_2_6_35_2","first-page":"421","article-title":"Clinically important nail psoriasis improvements are achieved with adalimumab (Humira\u00ae): results from a large open\u2010label prospective study (STEREO)","volume":"66","author":"Van den Bosch F","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_36_2","unstructured":"MartinsGet\u00a0al.(Title) WCD 2007 Poster 5279."},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.01.101"},{"key":"e_1_2_6_38_2","first-page":"339","article-title":"Alafacept in the treatment of psoriatic nail disease: a proof of concept study","volume":"5","author":"Parrish CA","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08686.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2009.03364.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2009.03364.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T04:18:55Z","timestamp":1694578735000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2009.03364.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,11]]},"references-count":39,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1111\/j.1468-3083.2009.03364.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03364.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,11]]}}}